1. Home
  2. NAT vs TBPH Comparison

NAT vs TBPH Comparison

Compare NAT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nordic American Tankers Limited

NAT

Nordic American Tankers Limited

HOLD

Current Price

$5.71

Market Cap

914.8M

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.36

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAT
TBPH
Founded
1995
2013
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
914.8M
824.9M
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
NAT
TBPH
Price
$5.71
$16.36
Analyst Decision
Hold
Buy
Analyst Count
2
6
Target Price
$3.25
$18.40
AVG Volume (30 Days)
5.2M
510.5K
Earning Date
05-28-2026
05-07-2026
Dividend Yield
7.91%
N/A
EPS Growth
N/A
279.13
EPS
N/A
2.06
Revenue
N/A
$15,386,000.00
Revenue This Year
$77.72
$1.04
Revenue Next Year
N/A
N/A
P/E Ratio
$525.49
$8.03
Revenue Growth
N/A
N/A
52 Week Low
$2.39
$8.32
52 Week High
$6.34
$21.03

Technical Indicators

Market Signals
Indicator
NAT
TBPH
Relative Strength Index (RSI) 52.84 56.03
Support Level $3.21 $13.41
Resistance Level $6.34 $19.04
Average True Range (ATR) 0.32 0.51
MACD -0.02 0.30
Stochastic Oscillator 42.86 74.59

Price Performance

Historical Comparison
NAT
TBPH

About NAT Nordic American Tankers Limited

Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: